MarketPulse

amyotrophic lateral sclerosis

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Keros Therapeutics' Rinvatercept Shows Promise in Neuromuscular Disease Trial

Keros Therapeutics presented Phase 1 data for rinvatercept showing good tolerability and increased muscle mass, planning Phase 2 trials in DMD and ALS.
KROSPhase 1 clinical trialPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

CervoMed's neflamapimod gains inclusion in UK's accelerated ALS clinical trial platform

CervoMed's neflamapimod selected for UK's accelerated EXPERTS-ALS trial platform. The drug will be evaluated in 35-80 ALS patients over 18-24 weeks.
CRVOclinical trialALS